Coronary Heart Disease in HIV-Infected Patients

Currently, there are methods of drug exposure to the infection caused by the human immunodeficiency viruses (HIV), that allow to suppress the active replication of the virus in the patient's body. The era of antiretroviral therapy, which has allowed HIV-infected people to live longer, has begun...

Full description

Bibliographic Details
Main Authors: M. A. Arzhakova, T. A. Shekhovtsova, D. V. Duplyakov
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2020-01-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Subjects:
Online Access:https://www.rpcardio.com/jour/article/view/2083
id doaj-147a540fe620406896804f919e5a1311
record_format Article
spelling doaj-147a540fe620406896804f919e5a13112021-09-03T13:15:30ZengStolichnaya Izdatelskaya KompaniyaRacionalʹnaâ Farmakoterapiâ v Kardiologii1819-64462225-36532020-01-0115690090510.20996/1819-6446-2019-15-6-900-9051685Coronary Heart Disease in HIV-Infected PatientsM. A. Arzhakova0T. A. Shekhovtsova1D. V. Duplyakov2Samara State Medical UniversitySamara State Medical UniversitySamara State Medical University; Samara Regional Clinical Cardiology DispensaryCurrently, there are methods of drug exposure to the infection caused by the human immunodeficiency viruses (HIV), that allow to suppress the active replication of the virus in the patient's body. The era of antiretroviral therapy, which has allowed HIV-infected people to live longer, has begun. This led to an increase in their cardiovascular diseases, which occur at an earlier age and are more severe than in people without HIV. Specific or “nontraditional” risk factors damaging vascular wall occur in HIV patients along with traditional risk factors. These factors include: the negative impact of HIV on endothelium, an imbalance of inflammatory mediators, pathological immune activation, a decrease in the level of CD4 cells, a change in the number and function of platelets. The question of the effect of antiretroviral therapy on the occurrence of atherosclerotic vascular lesions remains debatable. Acute coronary syndrome (ACS) is one of the most frequent and most severe cardiovascular events in HIV-infected patients. The risk of myocardial infarction is highest in patients with a viral load of HIV-1 ribonucleic acid (RNA)≥500 copies/ml and a CD4 cell count of <200/ml. The most common form of ACS in HIV patients is ACS with ST segment elevation. Treatment of ACS in HIV patients has some difficulties: a high frequency of stent thrombosis, the frequent occurrence of thrombocytopenia, drug interactions with antiretroviral therapy. The high risk of developing cardiovascular diseases in HIV patients necessitates the introduction of active measures of primary and secondary prevention, taking into account the specific interaction of all drugs taken by the patient.https://www.rpcardio.com/jour/article/view/2083hiv infectionmyocardial infarctionacute coronary syndrome
collection DOAJ
language English
format Article
sources DOAJ
author M. A. Arzhakova
T. A. Shekhovtsova
D. V. Duplyakov
spellingShingle M. A. Arzhakova
T. A. Shekhovtsova
D. V. Duplyakov
Coronary Heart Disease in HIV-Infected Patients
Racionalʹnaâ Farmakoterapiâ v Kardiologii
hiv infection
myocardial infarction
acute coronary syndrome
author_facet M. A. Arzhakova
T. A. Shekhovtsova
D. V. Duplyakov
author_sort M. A. Arzhakova
title Coronary Heart Disease in HIV-Infected Patients
title_short Coronary Heart Disease in HIV-Infected Patients
title_full Coronary Heart Disease in HIV-Infected Patients
title_fullStr Coronary Heart Disease in HIV-Infected Patients
title_full_unstemmed Coronary Heart Disease in HIV-Infected Patients
title_sort coronary heart disease in hiv-infected patients
publisher Stolichnaya Izdatelskaya Kompaniya
series Racionalʹnaâ Farmakoterapiâ v Kardiologii
issn 1819-6446
2225-3653
publishDate 2020-01-01
description Currently, there are methods of drug exposure to the infection caused by the human immunodeficiency viruses (HIV), that allow to suppress the active replication of the virus in the patient's body. The era of antiretroviral therapy, which has allowed HIV-infected people to live longer, has begun. This led to an increase in their cardiovascular diseases, which occur at an earlier age and are more severe than in people without HIV. Specific or “nontraditional” risk factors damaging vascular wall occur in HIV patients along with traditional risk factors. These factors include: the negative impact of HIV on endothelium, an imbalance of inflammatory mediators, pathological immune activation, a decrease in the level of CD4 cells, a change in the number and function of platelets. The question of the effect of antiretroviral therapy on the occurrence of atherosclerotic vascular lesions remains debatable. Acute coronary syndrome (ACS) is one of the most frequent and most severe cardiovascular events in HIV-infected patients. The risk of myocardial infarction is highest in patients with a viral load of HIV-1 ribonucleic acid (RNA)≥500 copies/ml and a CD4 cell count of <200/ml. The most common form of ACS in HIV patients is ACS with ST segment elevation. Treatment of ACS in HIV patients has some difficulties: a high frequency of stent thrombosis, the frequent occurrence of thrombocytopenia, drug interactions with antiretroviral therapy. The high risk of developing cardiovascular diseases in HIV patients necessitates the introduction of active measures of primary and secondary prevention, taking into account the specific interaction of all drugs taken by the patient.
topic hiv infection
myocardial infarction
acute coronary syndrome
url https://www.rpcardio.com/jour/article/view/2083
work_keys_str_mv AT maarzhakova coronaryheartdiseaseinhivinfectedpatients
AT tashekhovtsova coronaryheartdiseaseinhivinfectedpatients
AT dvduplyakov coronaryheartdiseaseinhivinfectedpatients
_version_ 1717816470571843584